| Ytd | 9.13% | |
| 1y | -46.10% |
| Open | 23.73 | Prev Close | 23.54 | Low | 23.73 | High | 23.73 | Mkt Cap | 4.35B |
| Vol | 10.17K | Avg Vol | 2.65M | EPS | -0.68 | P/E | -34.62 | Forward P/E | 149.25 |
| Beta | 0.34 | Short Ratio | 3.78 | Inst. Own | 53.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 29.08 | 200-d Avg | 25.00 | 1yr Est | 55.63 |
LEGN News
Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre
JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announce
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and
Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get th
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating
Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a glob
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with re
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a
Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T
LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors am
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a
Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing e
TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and raises the p
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and
Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.03) per share which missed the analyst
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a
During Wednesday's morning trading, 125 companies set new 52-week highs.